Dr Palpant said a subsequent study has put the drug through a series of preclinical tests designed to mimic real-life treatment scenarios.
Spider venom heart drug a step closer
Protects during a heart attack
“These tests are a major step towards helping us understand how Hi1a would work as a therapeutic – at what stage of a heart attack it could be used and what the doses should be,” Dr Palpant said.
“We established that Hi1a is as effective at protecting the heart as the only cardioprotective drug to reach Phase 3 clinical trials, a drug that was ultimately shelved due to side effects.
“Importantly, we found that Hi1a only interacts with cells in the injured zone of the heart during an attack and doesn’t bind to healthy regions of the heart – reducing the chance of side effects.”
Discovered in funnel web spider venom
Professor King, who recently won the Prime Minister’s Prize for Innovation for developing the world’s first insecticides from spider venom, discovered Hi1a in the venom of the K’gari funnel web spider.
“Hi1a could reduce damage to the heart and brain during heart attacks and strokes by preventing cell death caused by lack of oxygen,” Professor King said.
“Our testing and safety studies from independent contract research organisations has provided evidence that Hi1a could be an effective and safe therapeutic.”
Leading cause of death
Infensa Bioscience, a company co-founded by the researchers, raised $23 million in 2022 to develop Hi1a for commercial purposes.
Infensa CEO and UQ researcher, Associate Professor Mark Smythe, said cardiovascular disease is the leading cause of death globally.
No drugs on the market
“Most deaths from cardiovascular disease are caused by heart attacks and strokes, yet there are no drugs on the market that prevent the damage they cause,” Dr Smythe said.
“An effective drug to treat heart attacks would have worldwide impact, providing a breakthrough to improve the lives of millions of individuals living with heart disease.”
The research team included Dr Meredith Redd from IMB as well as Dr Melissa Reichelt and Dr Yusuke Yoshikawa from UQ’s School of Biomedical Sciences.
The research was funded by the Australian National Health and Medical Research Council, Australian Medical Research Future Fund, The University of Queensland, Infensa Bioscience, The Heart Foundation and The Lott by Golden Casket.
The study was published in the world’s leading cardiac journal The European Heart Journal.